Efficacy and tolerability of erlotinib 100 mg/d vs. gefitinib 250 mg/d in EGFR-mutated advanced non-small cell lung cancer (E100VG250): an open-label, randomized …
S Zhao, Z Zhang, W Fang, Y Zhang, Z Zhang… - Frontiers in …, 2020 - frontiersin.org
Background: Erlotinib-based combination therapy leads to increased efficacy but also
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
Methods: Patients with EGFR-mutated advanced NSCLC were randomized at 1: 1 ratio to receive erlotinib 100 mg/d or gefitinib 250 mg/d until disease progression or …
S Zhao, Z Zhang, W Fang, Y Zhang… - … Strategies in EGFR …, 2022 - books.google.com
Background: Erlotinib-based combination therapy leads to increased efficacy but also
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
toxicity for EGFR-mutated NSCLC. Reducing the dose of erlotinib could improve treatment …
Activity of erlotinib when dosed below the maximum tolerated dose for EGFR‐mutant lung cancer: Implications for targeted therapy development
BL Lampson, M Nishino, SE Dahlberg, D Paul… - Cancer, 2016 - Wiley Online Library
BACKGROUND Erlotinib is a standard first‐line therapy for patients who have metastatic
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
nonsmall cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations …
Reduced-dose versus full-dose erlotinib for advanced EGFR-mutant non-small cell lung carcinoma (NSCLC): A retrospective analysis.
8074 Background: Erlotinib is an EGFR tyrosine kinase inhibitor (TKI) which is FDA-
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …
approved at the maximum tolerated dose (MTD) of 150mg daily with dose limiting toxicities …
[HTML][HTML] Erlotinib at a dose of 25 mg daily for non-small cell lung cancers with EGFR mutations
Purpose The tyrosine kinase inhibitors (TKIs) gefitinib and erlotinib are effective in non-small
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
cell lung cancers (NSCLCs) with epidermal growth factor receptor (EGFR) gene mutations …
Effect of erlotinib plus bevacizumab vs erlotinib alone on progression-free survival in patients with advanced EGFR-mutant non–small cell lung cancer: a phase 2 …
TE Stinchcombe, PA Jänne, X Wang, EM Bertino… - JAMA …, 2019 - jamanetwork.com
Importance Erlotinib is a standard first-line therapy for patients with epidermal growth factor
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free …
Randomized phase II trial of erlotinib beyond progression in advanced erlotinib-responsive non-small cell lung cancer
Background. Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) therapy
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
is clearly beneficial in patients with advanced EGFR-mutated non-small cell lung cancer …
A randomized Phase 2 study to compare erlotinib with or without bevacizumab in previously untreated patients with advanced non–small cell lung cancer with EGFR …
Background This study evaluated whether an addition of bevacizumab to erlotinib improves
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
clinical outcomes in patients with advanced EGFR‐mutated non–small cell lung cancer …
A phase II study of erlotinib treatment in advanced non-small cell lung cancer after failure of gefitinib: Is a clinical benefit still achievable?
B Cho, C Im, H Choi, S Shin, J Sohn, J Kim… - Journal of Clinical …, 2007 - ascopubs.org
7609 Background: To evaluate the efficacy and toxicity of erlotinib in patients (pts) with
advanced NSCLC who had progression after treatment with gefitinib. Methods: The study …
advanced NSCLC who had progression after treatment with gefitinib. Methods: The study …
Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a …
C Zhou, YL Wu, G Chen, J Feng, XQ Liu… - The lancet …, 2011 - thelancet.com
Background Activating mutations in EGFR are important markers of response to tyrosine
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …
kinase inhibitor (TKI) therapy in non-small-cell lung cancer (NSCLC). The OPTIMAL study …